Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients

详细信息    查看全文

• 作者：Takehiro Kawata (1) (4)
  Akira Kanamori (1)
  Akira Kubota (1)
  Hajime Maeda (1)
  Hikaru Amamiya (1)
  Masahiko Takai (1)
  Hideaki Kaneshige (1)
  Fuyuki Minagawa (1)
  Kotaro Iemitsu (1)
  Mizuki Kaneshiro (1)
  Masashi Ishikawa (1)
  Hiroshi Takeda (1)
  Tetsurou Takuma (1)
  Atsuko Mokubo (1)
  Hideo Machimura (1)
  Mitsuo Obana (1)
  Masaaki Miyakawa (1)
  Yoshikazu Naka (1)
  Yasuo Terauchi (2)
  Masao Toyoda (3)
  Daisuke Suzuki (3)
  Yasushi Tanaka (4)
  Ikuro Matsuba (1) (5)
  
• 关键词：Body weight ; HbA1c ; Hypoglycemia ; Liraglutide
• 刊名：Diabetology International
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：5
• 期：2
• 页码：98-104
• 全文大小：
• 参考文献：1. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6?years-therapy of type II diabetes: a progressive disease. UK Diabetes. 1995;44(11):1249-8. CrossRef
  2. Butler AE, Janson J, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102-0. CrossRef
  3. Chan JC, Malik V, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129-0. CrossRef
  4. Sugii H, Matsumura Y, Inoue A, et al. Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza^?). Nihon Yakurigaku Zasshi. 2010;136:233-1. CrossRef
  5. Glauser DA, Schlegel W. The emerging role of FOXO transcription factors in pancreatic beta cells. J Endocrinol. 2007;193(2):195-07. CrossRef
  6. Jin T, Liu L. The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol. 2008;22(11):2383-2. CrossRef
  7. Seino Y, Rasmussen MF, et al. Efficacy and safety of the once daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010;26(5):1013-2. CrossRef
  8. Flint A, Raben A, Astrup A, et al. Glucagon like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-0. CrossRef
  9. Brubaker PL, Drucker DJ. Glucagon- like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145(6):2653-. CrossRef
  10. Wang Q, Brubaker PL. Glucagon- like peptide-1 treatment delays the onset of diabetes in 8?week-old db/db mice. Diabetologia. 2002;45(9):1263-3. CrossRef
  11. Garber A, Henry R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-1. CrossRef
  12. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1- studies. Diabetes Obes Metab. 2009;11:26-4. CrossRef
  13. Zinman B, Gerich J, Bose JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidine in patients with type 2 diabetes (LEAD-4 Met?+?TZD). Diabetes Care. 2009;32(7):1224-0. CrossRef
  14. Herman DW, Swern A, Davies MJ, et al. In patients with type 2 diabetes, sitagliptin effectively lowers A1c regardless of patient age, gender, or body mass index. Diabetes 2008;57(Suppl 1):A148 (Abstract 495-P).
  15. Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95(1):e20-.
  16. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12:780-. CrossRef
  17. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand. 1997;160:413-2. CrossRef
  18. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-1. CrossRef
  19. Seino Y, Rasmussen MF, Zdravkovic M, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81:161-. CrossRef
  20. Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:341-. CrossRef
  21. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and body weight in subjects with type 2 diabetes. Diabet Med. 2005;22:1016-3. CrossRef
  22. Marre M, Shaw J, Brandle M, The LEAD-1 SU Study Group, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26?weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-8. CrossRef
  23. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002;3(3):141-.
  24. Viberti G, Lachin J, Holman R, et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabet Med. 2006;23:1289-4.
  
• 作者单位：Takehiro Kawata (1) (4)
  Akira Kanamori (1)
  Akira Kubota (1)
  Hajime Maeda (1)
  Hikaru Amamiya (1)
  Masahiko Takai (1)
  Hideaki Kaneshige (1)
  Fuyuki Minagawa (1)
  Kotaro Iemitsu (1)
  Mizuki Kaneshiro (1)
  Masashi Ishikawa (1)
  Hiroshi Takeda (1)
  Tetsurou Takuma (1)
  Atsuko Mokubo (1)
  Hideo Machimura (1)
  Mitsuo Obana (1)
  Masaaki Miyakawa (1)
  Yoshikazu Naka (1)
  Yasuo Terauchi (2)
  Masao Toyoda (3)
  Daisuke Suzuki (3)
  Yasushi Tanaka (4)
  Ikuro Matsuba (1) (5)
  
  1. The Study Group of the Diabetes Committee, Kanagawa Physicians Association, 3F Kanagawa-ken, Sogo Iryo Kaikan, 3-1 Fujimi-cho, Naka-ward, Yokohama, Kanagawa, 231-0037, Japan
  4. Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan
  2. Department of Endocrinology and Diabetes, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ward, Yokohama, Kanagawa, 232-0024, Japan
  3. Division of Nephrology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimkasuya, Isehara, Kanagawa, 259-11, Japan
  5. Matsuba Medical Clinic, 2-159 Tsukagoshi, Saiwai-ward, Kawasaki, Kanagawa, 212-0024, Japan
  
• ISSN：2190-1686

文摘

Aims Our goal was to evaluate liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in monotherapy and combination therapy for Japanese type 2 diabetes patients. Materials and methods Patients with type 2 diabetes (111 men, 83 women; mean age 57.6?±?12.6?years) were treated with liraglutide and divided into liraglutide monotherapy (n?=?147 patients, group A) and liraglutide–sulfonylurea (SU) combination therapy (n?=?47, group B) groups. Changes in clinical parameters after liraglutide administration were evaluated. Results In both groups, significant decreases in glycosylated hemoglobin (HbA1c) were seen after 12 (group A, 7.01?±?1.38 vs. 7.72?±?1.57?%, p?<?0.01; group b, 7.83?±?1.19 vs. 8.44?±?1.47?%, p?<?0.01) and 24?weeks (group A, 7.21?±?1.45 vs. 7.72?±?1.57?%, p?<?0.01; group B, 7.79?±?1.22 vs. 8.44?±?1.47?%, p?<?0.01). In group A, body weight decreased significantly from before administration (74.5?±?19.2?kg) to 12?(73.0?±?17.8?kg) and 24?(72.8?±?17.6?kg) (p?<?0.01) weeks. In group B, body weight decreased significantly from before administration (71.4?±?17.4?kg) to 12?weeks (70.9?±?17.9?kg; p?<?0.01). Low-density lipoprotein (LDL) cholesterol decreased significantly in group A from before administration (112.6?±?34.2?mg/dl) to 12 (107.7?±?35.0?mg/dl; p?<?0.005) and 24 (106.3?±?26.8?mg/dl; p?<?0.05)?weeks. In group B, LDL cholesterol decreased significantly from before administration (112.1?±?24.7?mg/dl) to 12?weeks (99.7?±?24.7?mg/dl; p?<?0.05) only. In both groups, no significant differences in systolic and diastolic blood pressures were observed at 12 and 24?weeks compared with before administration. Adverse events after starting liraglutide occurred in 45 patients (23.2?%), 23 (11.9?%) discontinued treatment. Conclusions Once-daily liraglutide was well tolerated as monotherapy or combination therapy with SU, demonstrating superior glycemic control with a low rate of hypoglycemia and weight loss.